3 ms·
The problem with “do both”: if you give your control group PrEP, then you won’t be able to get data to support the vaccine’s efficacy. A trial requires enough i
by dhnajsjdnd 6y ago
The problem with “do both”: if you give your control group PrEP, then you won’t be able to get data to support the vaccine’s efficacy. A trial requires enough infections in the control group to show the vaccine is better.
- at_a_remove 6y agoThat's only a problem for the studies. I'm talking about after the studies. I can see a lot of at-risk people saying "Yeah, I'll do both." I was joking to my doctor that when I get access to the COVID vaccines, I plan on Moderna in one arm and Pfizer in the other.
- tempestn 6y agoThe comment you replied to was specifically asking how the trial would work given PrEP though.
- sjg007 6y agoYou pick a high risk group that either doesn’t have access to prep
- heavyset_go 6y agoFor the HIV vaccine trials, all participants are educated about and are offered free PrEP. There will be participants who choose not to take the PrEP anyway, and there will be people who are not compliant with PrEP's dosing schedule, which will reduce its efficacy against HIV acquisition.
- bluGill 6y agoDrugs are controlled against the alternative treatment often enough. The study needs to be designed differently, but statistics can do this.